India Biosimilar Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 17.38% (2025-2033)

India biosimilar industry is growing at a rapid pace owing to the rising demand for affordable biologics and favorable regulations. Research and development and manufacturing are also fueling market growth. According to the latest report by IMARC Group, the India biosimilar market size reached USD 866.2 million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,662.9 million by 2033, exhibiting a growth rate (CAGR) of 17.38% during 2025-2033.

Download a sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample

India Biosimilar Trends and Drivers:

The India biosimilar market is growing fast. This growth comes from the need for affordable biologics. Supportive government policies also play a role. Biosimilars are very similar to reference biologic drugs. They offer affordable ways to manage chronic diseases like cancer, diabetes, and autoimmune disorders. India's pharmaceutical industry is famous for making generic drugs. It uses its strong manufacturing skills to create high-quality biosimilars at lower prices. The market is expected to grow a lot. Estimates show a compound annual growth rate (CAGR) of over 20% for the next ten years. This growth comes from three main factors: higher healthcare spending, an aging population, and the expiration of patents for key biologics. These factors create chances for biosimilars to enter the market. CDSCO guidelines have made approval processes smoother. This has helped boost investor confidence. This is making India an important player in the global biosimilar market. Challenges like high development costs and tricky manufacturing processes still exist. They need ongoing innovation and investment.

India biosimilar market is influenced by changing trends in access and adoption. The rise of non-communicable diseases has made it important to have accessible treatments. Biosimilars are now a key part of India’s healthcare plan. Government programs like the National Health Policy and Ayushman Bharat seek to boost biosimilar use. This helps lower patients' out-of-pocket costs. Private companies are investing in doctor training and patient awareness. They want to build trust in biosimilar safety and effectiveness. The rise of contract manufacturing organizations (CMOs) in India is a key trend. They help smaller firms enter the market by outsourcing production. Export opportunities are growing. Indian biosimilars are becoming popular in regulated markets like the U.S. and Europe. Cost pressures are boosting demand. Competition is growing stronger, both at home and abroad. Companies must stand out. They can do this by improving delivery systems. Also, they should explore new therapeutic areas. India faces challenges despite opportunities. Strict rules in developed markets and pricing pressures create hurdles. To stay competitive, India needs strategic partnerships and ongoing quality improvements.

We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging India biosimilar market trends.

India Biosimilar Industry Segmentation:

The report has segmented the market into the following categories:

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Manufacturing Type Insights:

• In-house Manufacturing
• Contract Manufacturing

Regional Insights:

• North India
• West and Central India
• South India
• East and Northeast India

Competitive Landscape:

The competitive landscape of the industry has also been examined, along with the profiles of the key players.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current, and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St., Brooklyn, NY 11249, USA 

Email: sales@imarcgroup.com 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145